Extract

The primary objective of this study is to assess the potential efficacy (in terms of objective response) of single agent copanlisib in patients with relapsed or refractory DLBCL and assess the relationship between efficacy and a potentially predictive biomarker.

Inclusion criteria

• patients with relapsed or refractory diffuse large B cell lymphoma

Links

• euctr
• euctr
• ictrp
• euctr
• ictrp
• ictrp
• ictrp
• euctr
• euctr